OPPapers.com Essay Index >> Business >> Pfizer Inc. Business Analysis And Strategic Implications
We have many free term papers and essays on Pfizer Inc. Business Analysis And Strategic Implications. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
PFIZER INC. Business Analysis and Strategic Implications PFIZER INC. BUSINESS ANALYSIS AND STRATEGIC IMPLICATIONS OVERVIEW OF THE COMPANY Pfizer Inc. is a global
a reliable quality producer to attract more retailers to depend on its products. 3. Cott Business and Strategic Analysis 3.1 Cott Business Model Cott Corporation,
with examples of some of the recent merger and acquisition in the pharmaceutical sector: a) Pfizer Inc. agreed to buy Pharmacia Corp. for stock valued at $60 billion,
strategic partnerships. There is also the risk that the company will need to return to the capital markets again for more funds, diluting the ownership stake for
Chiron, a biotech firm based in San-Francisco, and some university research labs to develop the first genetically engineered vaccine for humans, a hepatitis B vaccine
Submitted by Brookside1 on April 19, 2007
Category: Business
Words: 3452 | Pages: 14
Views: 796
Popularity Rank: 11,510
Average Member Grade: N/A (Add a Comment / Grade this Paper)
PFIZER INC.
BUSINESS ANALYSIS
AND
STRATEGIC IMPLICATIONS
OVERVIEW OF THE COMPANY
Pfizer Inc. is a global pharmaceutical company that creates and manufactures products for both humans and animals. Pfizer is headquartered in New York City and employs about 115,000 people.
PRINCIPAL PRODUCTS AND SERVICES
Pfizer currently has ten different divisions and promotes thirty-one different major products. The divisions and largest major products within each group are: Cardiovascular and Metabolic Diseases (Lipitor, Caduet, Norvasc), Central Nervous System Disorders (Aricept, Geodon, Lyrica, Zoloft), Diabetes (Exubera), Arthritis and Pain (Celebrex), Infectious and Respiratory Diseases (Diflucan, Zithromax), Urology (Detrol, Viagra), Oncology (Sutent), Opthalmology (Macugen), Endocrine Disorders (Genotropin), All Other (Chantix, Zyrtec). In addition, Pfizer has six products that are in the late stage of the R&D pipeline: UK-427,857 for HIV treatment, Parecoxib for acute pain, Edotecarin for colorectal cancer, Torcetrapib/Lipitor for heart disease, Asenapine for bipolar disorder, and Zithromax-chloroquine for malaria.
PRESENT FINANCIAL CONDITION
Pfizer's overall present financial condition is not secure, but is trending positively for 2006 compared to the previous year. The positive trends are related to the major products the company has in its pipeline. "Pfizer is poised to introduce six new medicines in 2006, including three (Chantix (smoking cessation), Stutent (cancer), and Exubera (diabetes)) that have billion dollar-plus potential." An analysis of Pfizer's finances will include: revenues and growth, stock price, net income, budget for R&D, cash flow, and EPS.
First, Pfizer has seen a major decline in revenue growth over the past few years. Pfizer recorded revenues of $51,298 million during 2005, which was a decrease of 2.4% over 2004. The second quarter for 2006...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!